Phase II Trial of Nivolumab and Stereotactic Ablative Radiation Therapy (SAbR) for Metastatic Clear Cell Renal Cell Carcinoma (mRCC)
Phase of Trial: Phase II
Latest Information Update: 26 Feb 2018
At a glance
- Drugs Nivolumab (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 18 Nov 2016 Planned number of patients changed from 87 to 35.
- 24 Jun 2016 Status changed from not yet recruiting to recruiting.
- 08 Jun 2016 New trial record